E-therapeutics Plc (ETXPF)
E-therapeutics Plc operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GB. The stock last traded at $0.13, up 0.00% on the session, giving a market capitalisation of $76.0M. On trailing twelve-month figures it carries a trailing P/E of -4.71, a net margin of -3511.3%. Its beta of 0.42 implies it has historically moved less than the broad market.
E-therapeutics Plc is a UK-based company focused on drug discovery. The core of its work involves a sophisticated computational platform that employs in-silico screening and unique network models to identify and predict which compounds or biological targets can effectively alter relevant biological processes. Furthermore, the company is advancing an RNA interference (RNAi) platform designed for highly specific gene silencing. Founded in 2001, E-therapeutics Plc operates from its headquarters in London, United Kingdom.
E-therapeutics Plc is most often compared with the following Healthcare names: